US Patent

US11628150 — Nasal formulations of metoclopramide

Method of Use · Assigned to Evoke Pharma Inc · Expires 2029-12-22 · 4y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating disorders treatable with metoclopramide by administering nasal formulations of the drug.

USPTO Abstract

Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.

Drugs covered by this patent

Reglan (Metoclopramide Hydrochloride) · Hikma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2843`	—	Reglan

Patent Metadata

Patent number: US11628150
Jurisdiction: US
Classification: Method of Use
Expires: 2029-12-22
Drug substance claim: No
Drug product claim: Yes
Assignee: Evoke Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.